Trials / Terminated
TerminatedNCT01756924
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Arrevus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CEM-102 | |
| DRUG | IV or Oral standard of care antibiotics | |
| DRUG | Rifampin |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2012-12-28
- Last updated
- 2019-04-19
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01756924. Inclusion in this directory is not an endorsement.